Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

President Urges End To Corporate Inversions

This article was originally published in The Tan Sheet

Executive Summary

In his State of the Union speech, President Obama pledges to “close tax loopholes,” including his continuing efforts to ban U.S. firms from moving their tax headquarters overseas in corporate inversion deals. On the same day Democratic legislators introduced a bill to stop corporate inversions.

You may also be interested in...



Pfizer’s Allergan Play Could Deliver Tax-Inversion, But No OTCs

Pfizer and Allergan are in friendly merger talks, but the US likely will not be amiable about another pharma giant re-incorporating abroad. Should a deal happen, Allergan’s generic OTC business would not be included, says Teva, awaiting antitrust clearance to close its acquisition of the Irish firm’s generic operations.

Pfizer’s Allergan Play Could Deliver Tax-Inversion, But No OTCs

Pfizer and Allergan are in friendly merger talks, but the US likely will not be amiable about another pharma giant re-incorporating abroad. Should a deal happen, Allergan’s generic OTC business would not be included, says Teva, awaiting antitrust clearance to close its acquisition of the Irish firm’s generic operations.

Hack Attack On Hospital System Highlights Need For Device Cybersecurity

Chinese hackers recently broke into Community Health Systems’ IT system and stole patient data. Although they did not take device data in this instance, the hackers might have been after that, experts suggest, highlighting vulnerabilities for industry.

Topics

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel